Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852691 · ClinicalTrials.gov registry record · Phase 2
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 20
- Study locations
NCT05852691: Active Phase 2 study of Breast Cancer, sponsored by Hoffmann-La Roche.
NCT05852691 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 83 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05852691, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Nab-Paclitaxel
- DRUG Tobemstomig
Study Locations (20)
Other
- Centro de Investigaciones Médicas y Desarrollo LC S.R.L - Buenos Aires
- Fakultni Thomayerova nemocnice - Praha 4 - Krc
- Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH - Essen
- Dres. Andreas Köhler und Roswitha Fuchs - Langen
- Universitätsklinikum Ulm Am Michelsberg - Ulm
- Komarom-Eszergom Varmegyei Szent Borbala Korhaz - Tatabánya
- Hadassah University Hospital - Ein Kerem - Jerusaelm
- Sheba Medical Center - Ramat Gan
São Paulo
- Hospital de Cancer de Barretos - Barretos
- Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda - São Paulo
California
- Cancer Blood and Specialty Clinic - Los Alamitos
New York
- Memorial Sloan-Kettering Cancer Center - New York
North Carolina
- Novant Health Presbyterain Medical Center - Charlotte
South Dakota
- Avera Cancer Institute - Sioux Falls
Victoria
- Sunshine Hospital - St Albans
Goiás
- Hospital Araujo Jorge - Goiânia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
What the registry record for NCT05852691 still lists
NCT05852691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05852691 names 20 study sites across 12 states, led by Other, São Paulo, California.
Frequently Asked Questions
What is clinical trial NCT05852691 about?
NCT05852691 is a clinical study titled "A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer". The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negati...
What is the current status of trial NCT05852691?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2023-07-18. Estimated completion is 2026-10-31.
What conditions does trial NCT05852691 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05852691?
The interventions under investigation include: Pembrolizumab (DRUG), Nab-Paclitaxel (DRUG), Tobemstomig (DRUG).
Who is sponsoring clinical trial NCT05852691?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05852691 being conducted?
This trial has 20 study locations across California, New York, North Carolina, South Dakota, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05852691's enrollment target sits among peer trials
83 637th of 1224 higher than 587 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI